Edmond DE Rothschild Holding S.A. Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

Edmond DE Rothschild Holding S.A. trimmed its holdings in Eli Lilly and Company (NYSE:LLYGet Rating) by 19.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 69,239 shares of the company’s stock after selling 17,111 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Eli Lilly and were worth $22,449,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Eli Lilly and by 1.8% during the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. FMR LLC lifted its stake in Eli Lilly and by 2.9% during the second quarter. FMR LLC now owns 32,439,666 shares of the company’s stock worth $10,517,913,000 after purchasing an additional 898,976 shares in the last quarter. Capital World Investors lifted its stake in Eli Lilly and by 17.0% during the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Jennison Associates LLC lifted its stake in Eli Lilly and by 31.1% during the second quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock worth $3,358,396,000 after purchasing an additional 2,456,760 shares in the last quarter. Finally, Capital International Investors lifted its stake in Eli Lilly and by 30.5% during the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares in the last quarter. 82.45% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Stock Performance

Shares of LLY stock traded up $0.84 during mid-day trading on Thursday, hitting $361.72. 1,993,218 shares of the stock were exchanged, compared to its average volume of 3,419,741. The stock’s fifty day simple moving average is $338.86 and its two-hundred day simple moving average is $321.23. The stock has a market capitalization of $343.70 billion, a price-to-earnings ratio of 54.31, a P/E/G ratio of 2.27 and a beta of 0.36. Eli Lilly and Company has a 12-month low of $231.87 and a 12-month high of $369.80. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13.

Eli Lilly and Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Monday, November 14th. Eli Lilly and’s payout ratio is 58.86%.

Analyst Ratings Changes

A number of research analysts have commented on LLY shares. Truist Financial upped their price target on Eli Lilly and from $400.00 to $421.00 in a research note on Tuesday, November 15th. Berenberg Bank increased their price objective on Eli Lilly and from $345.00 to $375.00 and gave the company a “buy” rating in a research note on Tuesday. StockNews.com assumed coverage on Eli Lilly and in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. The Goldman Sachs Group increased their price objective on Eli Lilly and from $281.00 to $313.00 and gave the company a “neutral” rating in a research note on Tuesday, November 8th. Finally, BMO Capital Markets increased their price objective on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research note on Tuesday, September 6th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and presently has an average rating of “Moderate Buy” and an average target price of $359.78.

Insiders Place Their Bets

In other Eli Lilly and news, EVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $326.23, for a total transaction of $214,006.88. Following the transaction, the executive vice president now owns 6,950 shares of the company’s stock, valued at $2,267,298.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $326.23, for a total transaction of $214,006.88. Following the transaction, the executive vice president now owns 6,950 shares of the company’s stock, valued at $2,267,298.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 149,264 shares of the firm’s stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $334.54, for a total value of $49,934,778.56. Following the transaction, the insider now directly owns 103,624,546 shares in the company, valued at approximately $34,666,555,618.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 571,297 shares of company stock valued at $193,929,777. 0.12% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.